Literature DB >> 73075

D.D.A.V.P. in haemophilia.

P M Mannucci, Z M Ruggeri, F I Pareti, A Capitanio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73075     DOI: 10.1016/s0140-6736(77)91555-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  A replicate study design for testing bioequivalence: a case study on two desmopressin nasal spray preparations.

Authors:  Christian Joukhadar; Barbara Schenk; Stefan T Kaehler; Christian J Kollenz; Peter Bauer; Markus Müller; Hans-Georg Eichler
Journal:  Eur J Clin Pharmacol       Date:  2003-10-17       Impact factor: 2.953

2.  The diagnosis and treatment of von Willebrand disease in children.

Authors:  Robert J Klaassen; Jacqueline M Halton
Journal:  Paediatr Child Health       Date:  2002-04       Impact factor: 2.253

3.  Management of severe chronic thrombocytopenia in von Willebrand's disease type 2B.

Authors:  C Mauz-Körholz; U Budde; H Kruck; D Körholz; U Göbel
Journal:  Arch Dis Child       Date:  1998-03       Impact factor: 3.791

Review 4.  Desmopressin (DDAVP) and hemostasis.

Authors:  S Lethagen
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

5.  The subcutaneous administration of the vasopressin analogue 1-desamino-8-D-arginine vasopressin in patients with von Willebrand's disease and hemophilia.

Authors:  M Köhler; P Hellstern; B Reiter; G von Blohn; E Wenzel
Journal:  Klin Wochenschr       Date:  1984-06-01

6.  Pharmacokinetics and haematological effects of desmopressin.

Authors:  M Köhler; A Harris
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Current management of von Willebrand's disease.

Authors:  G Castaman; F Rodeghiero
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.